Pyoderma gangrenosum in a patient with primary cutaneous peripheral T-cell lymphoma, not otherwise specified

Eur J Dermatol. 2012 Nov-Dec;22(6):792-3. doi: 10.1684/ejd.2012.1862.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Anti-Inflammatory Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cyclosporine / therapeutic use
  • Dermatologic Agents / therapeutic use
  • Doxorubicin / administration & dosage
  • Fatal Outcome
  • Humans
  • Lymphoma, T-Cell, Cutaneous / complications
  • Lymphoma, T-Cell, Cutaneous / drug therapy
  • Lymphoma, T-Cell, Cutaneous / pathology*
  • Male
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use
  • Pyoderma Gangrenosum / complications
  • Pyoderma Gangrenosum / drug therapy
  • Pyoderma Gangrenosum / pathology*
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology*
  • Vincristine / administration & dosage

Substances

  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Vincristine
  • Doxorubicin
  • Cyclosporine
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • VAP-cyclo protocol